about
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseasesBiologic agents in juvenile spondyloarthropathiesEULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation.Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes.Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center.HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis.Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.Consensus-based recommendations for the management of juvenile dermatomyositis.Monogenic autoinflammatory diseases.Recommendations for the management of autoinflammatory diseases.2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Coll2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Coll2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric RheumatologyDevelopment of the autoinflammatory disease damage index (ADDI).The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry.[Autoinflammatory diseases].Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients.Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept.Multicentric prevalence study of anti P ribosomal autoantibodies in juvenile onset systemic lupus erythematosus compared with adult onset systemic lupus erythematosus.Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.Neuromyelitis optica associated with systemic autoimmune diseases in children.13.4 High frequency of CNS involvement in linear scleroderma of the face.14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE).Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy.Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.PReS-FINAL-2120: Juvenile scleroderma international network (JUSINET) database: a reliable instrument for clinical research in juvenile scleroderma syndromes.The juvenile systemic sclerosis clinic: an interdisciplinary approach.Systemic juvenile idiopathic arthritis is associated with HLA-DRB1 in Europeans and Americans of European descent.Classification of juvenile spondyloarthropaties according to asas criteria.SHARE – workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile dermatomyositis.SHARE – workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile localized scleroderma and juvenile systemic sclerosis.Share – Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis.A preliminary disease severity score for juvenile systemic sclerosis.Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.Localized scleroderma in childhood is not just a skin disease.Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric RheumatologyBlau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series.PReS-FINAL-2236: Continuous autoinflammatory syndromes: a single-center experience in Argentina.IL1RN Variation Influences both Disease Susceptibility and Response to Human Recombinant IL-1RA Therapy in Systemic Juvenile Idiopathic Arthritis.
P50
Q24337040-BE592F37-ABA2-4D9A-B31B-76DDC59E642FQ26766263-04EE7018-496C-41CB-B8AC-A3A08FC914ADQ34109962-19AECAB6-6DF8-403E-9B79-15B75E37122BQ35443835-BA700FF9-ECB0-4EFA-8509-B3631B6CABE3Q35794649-F5250CD3-ED7D-4F12-8D07-95EA8B97BDF1Q36435134-DBF23CEB-2301-467D-A6FB-3DD691995455Q36517235-B72B6EFB-A109-4236-B61B-9453F3ACFDBDQ37617000-1ACAC4EA-49D7-427A-9F19-83CFEBEB17D6Q38211947-836A3CC1-84F3-4180-B1B0-B10A18ABCFE8Q38537504-C2D57858-C6F8-46CA-8339-F539D8A3E6AAQ38575277-76722F4E-69C7-4C30-AB95-938DEF95BA5CQ38729149-5DBBD108-B5F1-4615-BF87-A284F9FA1A5AQ38849148-FE78CF27-2753-43DD-A58F-5B141A143DF3Q38997969-6C52D638-E8FB-4DE6-8E81-4FFC196641A8Q39744124-CFF4987A-AE35-4D97-8FEA-9803ABBA8266Q40101650-E8B54CB9-2021-48B6-895F-51A68C53A314Q40198507-2ED1C3E4-19FF-4902-913E-EB0DCAE540A5Q40501459-012F3FF5-A2F2-49E4-8F9E-18F849AEABA8Q44632590-AA2E7003-5E0C-4020-8E83-63E7EA48B074Q45325652-38B73610-42A3-4FF3-8168-D229A11B0896Q45745313-79F34A84-0619-4FEB-B9A0-F4CDEE4CF014Q45746300-506B8F52-187F-456E-ACFC-CFF5D0A98C2AQ45746310-494BD1EF-0FDA-49B2-AA5A-435C228148FBQ45803593-F464ED4D-260F-4295-A65D-BA0DEF444D99Q45840736-AA7DED88-9414-41A5-867E-D4F35A80F190Q45919305-7246C288-2667-4B3D-ACEC-A513B2BC41A0Q46380233-CC590BE1-5EF9-45F1-AE46-260571C647DEQ46381425-48A6F71A-8615-46CC-A5FB-5B21EECC71AEQ46860744-9E6AFDFA-76AD-435B-8CCE-3BC22F3716EDQ46864301-DDA9F527-76A6-461D-BB21-99AFD7A2046BQ46962211-B0066231-D518-4ECA-B193-ACA193085AD3Q46966573-C6469F57-70CD-4A06-80BC-8632DB0D85CCQ47271808-4081D5C6-C330-4BCC-AF00-9D8D2178BC55Q47689325-AF1AC2D9-31E8-4AA0-BFE5-DA249CCB5C2EQ47733634-4369861F-A21B-43E6-84D8-EB7C4DEE16E5Q47818655-E267FC16-3B1F-4EB4-BE0E-4577AA178BE8Q47924181-047D3649-2F88-409D-8F38-24A1CD6951E0Q48011327-3A49C451-26F9-4589-8FEF-CE40FD21E724Q50321168-2913150A-ED4B-41A0-8CDD-3893DBA9172EQ52612756-9F0153A9-DFF3-4F36-AAD5-6E79C03D619B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ricardo Russo
@ast
Ricardo Russo
@en
Ricardo Russo
@es
Ricardo Russo
@nl
Ricardo Russo
@sl
type
label
Ricardo Russo
@ast
Ricardo Russo
@en
Ricardo Russo
@es
Ricardo Russo
@nl
Ricardo Russo
@sl
prefLabel
Ricardo Russo
@ast
Ricardo Russo
@en
Ricardo Russo
@es
Ricardo Russo
@nl
Ricardo Russo
@sl
P106
P1153
7201443428
P21
P31
P496
0000-0002-1256-8483